Alterations of the c-myc genomic region are usually observed in prostate cancer [39-41] and bladder cancer [42], however, genomic alterations of c-myc are mostly subordinate for conventional RCC with the exception of papillary renal cancer [43-45]. This evidence concerns the gene MYC and renal cell carcinoma.